Financials
Financial year 2025
CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE from Anderlecht, company number BE0403057962, closed financial year 2025 with a result of € -264,144 after tax. For that financial year CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE recorded revenue of € 580.7 million and equity of € 11.6 million. Compared with financial year 2024, the result moved from € 383,842 to € -264,144. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 9, 2026.
€ 11.6 million
▼ 2% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -264,144
▼ still € 383,842 profit in 2024
Profit after tax over the fiscal year.
€ 2.4 million
▲ 22% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 384,880.
People and assets in 2025
243.9
▲ 11.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 13.5 million
▲ 8% vs 2024
€ 55,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 4.6 million
▼ 11% vs 2024
Of which on lease € 3.5 million.
Debts at end 2025
€ 58.2 million
▲ 10% vs 2024
€ 909,214 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 53 million
▲ 18% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 34 days on average.
€ 1.4 million
▲ 14% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 415,731,389 | € 460,373,997 | € 517,896,627 | € 580,721,056 | ▲ 12% |
| Profit after taxes | € 313,799 | € -77,193 | € 383,842 | € -264,144 | ▼ € 647,985 |
| Equity | € 11,575,194 | € 11,498,001 | € 11,881,843 | € 11,617,699 | ▼ 2% |
| Total debts | € 92,023,975 | € 99,514,735 | € 102,518,719 | € 116,074,205 | ▲ 13% |
| Cash | € 2,163,926 | € 1,494,916 | € 2,006,693 | € 2,439,399 | ▲ 22% |
| Land & buildings | € 3,889,007 | € 7,208,957 | € 7,704,586 | € 7,428,170 | ▼ 4% |
| Retained profit | € 342,376 | € 265,182 | € 649,024 | € 384,880 | ▼ 41% |
| Bank debt | € 47,267,672 | € 49,562,597 | € 52,838,097 | € 58,154,280 | ▲ 10% |
| Balance sheet total | € 104,641,166 | € 111,057,435 | € 114,460,900 | € 127,732,098 | ▲ 12% |
| Employees (FTE) | 224.1 | 228.7 | 232.5 | 243.9 | ▲ 11.4 |
Key figures of CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE?
What happened at CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- CHRISTOPHE LEFEVRE stepped down as director. NBB
- ARMAND PINTON stepped down as director. NBB
- PAUL RANSART stepped down as director. NBB
- SOBEDIP SA stepped down as director. NBB
- BERTRAND BUSSY stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 264,144 (▼ € 647,985 vs 2024). Source: NBB ↗
- ANNE VALETTE stepped down as director. NBB
- ANNE VALETTE became a director. NBB
In short
From € 313,799 profit in 2022 to € 264,144 loss in 2025.
Paid € 428,611 in corporate taxes since 2022.
Best year ever: 2024, with € 383,842 profit.
Pays suppliers within 34 days on average.
A new publication or filing at CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE? We notify you, reason included.
Follow CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by SOBEDIP SA (100%) and TIERS AUTRE (0%).
Directors
According to the 2025 annual accounts
PAUL RANSART
Director
since 2022 · until 2028
ANNE VALETTE
Director
since 2023 · until 2026
since 2022 · until 2028
CHRISTOPHE LEFEVRE
Director
since 2023 · until 2029
ARMAND PINTON
Director
since 2023 · until 2029
since 2022 · until 2028
Shareholders
100%
TIERS AUTRE
0%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Humaniteitslaan 55
1070 Anderlecht
Rue Henri Lemaire(FB) 13 box A
7911 Frasnes-lez-Anvaing
Active since 8 August 1994
Middelweg 90
1130 Brussel
Active since 1 January 2000
Rue de Liège(CO) 31
6180 Courcelles
Active since 30 September 1994
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0403.057.962
- VAT number
- BE 0403.057.962
- Registered office
- Humaniteitslaan 55, 1070 Anderlecht
- Names & denominations
- CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE · CERP
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 January 1968
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen